PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD
Status:
Terminated
Trial end date:
2019-08-30
Target enrollment:
Participant gender:
Summary
This will be a randomized, open-label, active-controlled, single dose crossover study with
either three or four treatment periods. Investigational treatment is with Dance 501 Human
Insulin Inhalation Solution (Dance 501) and the comparator is Insulin Lispro (Humalog®).
Target population will be Non-Diabetic individuals with mild to moderate asthma or chronic
obstructive pulmonary disease (COPD) and non-diabetic individuals without underlying lung
disease (healthy subjects).